Psychoactive Substances - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511251820

Publication Date:

November 19, 2024

Pages:

116

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Psychoactive Substances was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Psychoactive Substances was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Psychoactive Substances was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Psychoactive Substances was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Psychoactive Substances include Zynerba Pharmaceuticals, GW Pharmaceuticals PLC., Enecta., Teewinot Life Sciences, GD Pharma, Cape Bouvard Technologies Pty Ltd, AusCann Group Holdings Pty Ltd., Cannabics Pharmaceuticals Inc. and Alpha-CAT, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Psychoactive Substances, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Psychoactive Substances by region & country, by Type, and by Application.
The Psychoactive Substances market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Psychoactive Substances.
麻豆原创 Segmentation
By Company
Zynerba Pharmaceuticals
GW Pharmaceuticals PLC.
Enecta.
Teewinot Life Sciences
GD Pharma
Cape Bouvard Technologies Pty Ltd
AusCann Group Holdings Pty Ltd.
Cannabics Pharmaceuticals Inc.
Alpha-CAT
Tilray
Cyrelian Pty Ltd.
MedReleaf Australia
Segment by Type:
Stimulants
Cannabinoids
Hallucinogens
Depressants
Segment by Application
Cancer
Neuropathic Disorders
Spasticity
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Psychoactive Substances manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Psychoactive Substances in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Psychoactive Substances in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Psychoactive Substances Product Introduction
1.2 Global Psychoactive Substances 麻豆原创 Size Forecast
1.3 Psychoactive Substances 麻豆原创 Trends & Drivers
1.3.1 Psychoactive Substances Industry Trends
1.3.2 Psychoactive Substances 麻豆原创 Drivers & Opportunity
1.3.3 Psychoactive Substances 麻豆原创 Challenges
1.3.4 Psychoactive Substances 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Psychoactive Substances Players Revenue Ranking (2023)
2.2 Global Psychoactive Substances Revenue by Company (2019-2024)
2.3 Key Companies Psychoactive Substances Manufacturing Base Distribution and Headquarters
2.4 Key Companies Psychoactive Substances Product Offered
2.5 Key Companies Time to Begin Mass Production of Psychoactive Substances
2.6 Psychoactive Substances 麻豆原创 Competitive Analysis
2.6.1 Psychoactive Substances 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Psychoactive Substances Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychoactive Substances as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Stimulants
3.1.2 Cannabinoids
3.1.3 Hallucinogens
3.1.4 Depressants
3.2 Global Psychoactive Substances Sales Value by Type
3.2.1 Global Psychoactive Substances Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Psychoactive Substances Sales Value, by Type (2019-2030)
3.2.3 Global Psychoactive Substances Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Cancer
4.1.2 Neuropathic Disorders
4.1.3 Spasticity
4.2 Global Psychoactive Substances Sales Value by Application
4.2.1 Global Psychoactive Substances Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Psychoactive Substances Sales Value, by Application (2019-2030)
4.2.3 Global Psychoactive Substances Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Psychoactive Substances Sales Value by Region
5.1.1 Global Psychoactive Substances Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Psychoactive Substances Sales Value by Region (2019-2024)
5.1.3 Global Psychoactive Substances Sales Value by Region (2025-2030)
5.1.4 Global Psychoactive Substances Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Psychoactive Substances Sales Value, 2019-2030
5.2.2 North America Psychoactive Substances Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Psychoactive Substances Sales Value, 2019-2030
5.3.2 Europe Psychoactive Substances Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Psychoactive Substances Sales Value, 2019-2030
5.4.2 Asia Pacific Psychoactive Substances Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Psychoactive Substances Sales Value, 2019-2030
5.5.2 South America Psychoactive Substances Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Psychoactive Substances Sales Value, 2019-2030
5.6.2 Middle East & Africa Psychoactive Substances Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Psychoactive Substances Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Psychoactive Substances Sales Value
6.3 United States
6.3.1 United States Psychoactive Substances Sales Value, 2019-2030
6.3.2 United States Psychoactive Substances Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Psychoactive Substances Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Psychoactive Substances Sales Value, 2019-2030
6.4.2 Europe Psychoactive Substances Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Psychoactive Substances Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Psychoactive Substances Sales Value, 2019-2030
6.5.2 China Psychoactive Substances Sales Value by Type (%), 2023 VS 2030
6.5.3 China Psychoactive Substances Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Psychoactive Substances Sales Value, 2019-2030
6.6.2 Japan Psychoactive Substances Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Psychoactive Substances Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Psychoactive Substances Sales Value, 2019-2030
6.7.2 South Korea Psychoactive Substances Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Psychoactive Substances Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Psychoactive Substances Sales Value, 2019-2030
6.8.2 Southeast Asia Psychoactive Substances Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Psychoactive Substances Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Psychoactive Substances Sales Value, 2019-2030
6.9.2 India Psychoactive Substances Sales Value by Type (%), 2023 VS 2030
6.9.3 India Psychoactive Substances Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Zynerba Pharmaceuticals
7.1.1 Zynerba Pharmaceuticals Profile
7.1.2 Zynerba Pharmaceuticals Main Business
7.1.3 Zynerba Pharmaceuticals Psychoactive Substances Products, Services and Solutions
7.1.4 Zynerba Pharmaceuticals Psychoactive Substances Revenue (US$ Million) & (2019-2024)
7.1.5 Zynerba Pharmaceuticals Recent Developments
7.2 GW Pharmaceuticals PLC.
7.2.1 GW Pharmaceuticals PLC. Profile
7.2.2 GW Pharmaceuticals PLC. Main Business
7.2.3 GW Pharmaceuticals PLC. Psychoactive Substances Products, Services and Solutions
7.2.4 GW Pharmaceuticals PLC. Psychoactive Substances Revenue (US$ Million) & (2019-2024)
7.2.5 GW Pharmaceuticals PLC. Recent Developments
7.3 Enecta.
7.3.1 Enecta. Profile
7.3.2 Enecta. Main Business
7.3.3 Enecta. Psychoactive Substances Products, Services and Solutions
7.3.4 Enecta. Psychoactive Substances Revenue (US$ Million) & (2019-2024)
7.3.5 Teewinot Life Sciences Recent Developments
7.4 Teewinot Life Sciences
7.4.1 Teewinot Life Sciences Profile
7.4.2 Teewinot Life Sciences Main Business
7.4.3 Teewinot Life Sciences Psychoactive Substances Products, Services and Solutions
7.4.4 Teewinot Life Sciences Psychoactive Substances Revenue (US$ Million) & (2019-2024)
7.4.5 Teewinot Life Sciences Recent Developments
7.5 GD Pharma
7.5.1 GD Pharma Profile
7.5.2 GD Pharma Main Business
7.5.3 GD Pharma Psychoactive Substances Products, Services and Solutions
7.5.4 GD Pharma Psychoactive Substances Revenue (US$ Million) & (2019-2024)
7.5.5 GD Pharma Recent Developments
7.6 Cape Bouvard Technologies Pty Ltd
7.6.1 Cape Bouvard Technologies Pty Ltd Profile
7.6.2 Cape Bouvard Technologies Pty Ltd Main Business
7.6.3 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Products, Services and Solutions
7.6.4 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Revenue (US$ Million) & (2019-2024)
7.6.5 Cape Bouvard Technologies Pty Ltd Recent Developments
7.7 AusCann Group Holdings Pty Ltd.
7.7.1 AusCann Group Holdings Pty Ltd. Profile
7.7.2 AusCann Group Holdings Pty Ltd. Main Business
7.7.3 AusCann Group Holdings Pty Ltd. Psychoactive Substances Products, Services and Solutions
7.7.4 AusCann Group Holdings Pty Ltd. Psychoactive Substances Revenue (US$ Million) & (2019-2024)
7.7.5 AusCann Group Holdings Pty Ltd. Recent Developments
7.8 Cannabics Pharmaceuticals Inc.
7.8.1 Cannabics Pharmaceuticals Inc. Profile
7.8.2 Cannabics Pharmaceuticals Inc. Main Business
7.8.3 Cannabics Pharmaceuticals Inc. Psychoactive Substances Products, Services and Solutions
7.8.4 Cannabics Pharmaceuticals Inc. Psychoactive Substances Revenue (US$ Million) & (2019-2024)
7.8.5 Cannabics Pharmaceuticals Inc. Recent Developments
7.9 Alpha-CAT
7.9.1 Alpha-CAT Profile
7.9.2 Alpha-CAT Main Business
7.9.3 Alpha-CAT Psychoactive Substances Products, Services and Solutions
7.9.4 Alpha-CAT Psychoactive Substances Revenue (US$ Million) & (2019-2024)
7.9.5 Alpha-CAT Recent Developments
7.10 Tilray
7.10.1 Tilray Profile
7.10.2 Tilray Main Business
7.10.3 Tilray Psychoactive Substances Products, Services and Solutions
7.10.4 Tilray Psychoactive Substances Revenue (US$ Million) & (2019-2024)
7.10.5 Tilray Recent Developments
7.11 Cyrelian Pty Ltd.
7.11.1 Cyrelian Pty Ltd. Profile
7.11.2 Cyrelian Pty Ltd. Main Business
7.11.3 Cyrelian Pty Ltd. Psychoactive Substances Products, Services and Solutions
7.11.4 Cyrelian Pty Ltd. Psychoactive Substances Revenue (US$ Million) & (2019-2024)
7.11.5 Cyrelian Pty Ltd. Recent Developments
7.12 MedReleaf Australia
7.12.1 MedReleaf Australia Profile
7.12.2 MedReleaf Australia Main Business
7.12.3 MedReleaf Australia Psychoactive Substances Products, Services and Solutions
7.12.4 MedReleaf Australia Psychoactive Substances Revenue (US$ Million) & (2019-2024)
7.12.5 MedReleaf Australia Recent Developments
8 Industry Chain Analysis
8.1 Psychoactive Substances Industrial Chain
8.2 Psychoactive Substances Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Psychoactive Substances Sales Model
8.5.2 Sales Channel
8.5.3 Psychoactive Substances Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Zynerba Pharmaceuticals
GW Pharmaceuticals PLC.
Enecta.
Teewinot Life Sciences
GD Pharma
Cape Bouvard Technologies Pty Ltd
AusCann Group Holdings Pty Ltd.
Cannabics Pharmaceuticals Inc.
Alpha-CAT
Tilray
Cyrelian Pty Ltd.
MedReleaf Australia

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.